Stock Detail
SIGA TECHNOLOGIES INC
Drug Manufacturers Other
SIGA @ Yahoo Finance | SIGA Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $2.48 | $2.66 | $-0.18 | -6.77% | 0.00 | $2.66 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $2.64 | $2.40 | 885,663 | 127.52M | 718,444.5 | 5.34 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 2.77 | 2.62 | 2.51 | 2.36 | 2.25 |
Stock Profile
SIGA Technologies, Inc. engages in the discovery, development, and commercialization of vaccines, antibiotics, and novel anti-infectives for the prevention and treatment of infectious diseases. It applies bacterial and viral genomics in the design and development of its products. The company offers products for use in defense against biological warfare agents, such as Smallpox and Arenaviruses. It has developed two methods in the development of vaccines, bacterial commensal vectors, which enables rapid production of live recombinant vaccines against biological agents; and surface protein expression system, used in the production of foreign proteins for use in subunit vaccine formulations. The company is also developing antibiotics to hit the bacterial adhesion organelles, as well as a technology for the mucosal delivery of its vaccines, which would allow the vaccines to activate the immune system at the mucus lined surfaces of the body, including the mouth, the nose, the lungs, and the gastrointestinal and urogenital tracts. The company's anti-infective product portfolio includes gram-positive antibiotic technology, gram-negative antibiotic technology, and broad-spectrum antibiotic technology targeted principally towards drug-resistant bacteria and hospital-acquired infections. SIGA Technologies has license agreements and collaborative research arrangements with Rockefeller University, Oregon State University, National Institutes of Health, Washington University, Regents of the University of California, and TransTech Pharma, Inc. The company was founded in 1995 and is headquartered in New York City.